[Japan's First] Selected as a 'GENIAC-PRIZE' Finalist, Unique in the Pharmaceutical Field and Technical Document Handling.

"GENIAC-PRIZE" is a project led by the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO), aimed at strengthening domestic generative AI development capabilities and promoting social implementation.

Ingenta Inc. (Headquarters: Tokyo, hereinafter "Ingenta") has been selected as one of the 8 finalists out of 58 applications in "Theme I: Formalization of Tacit Knowledge in Manufacturing" of the "GENIAC-PRIZE" generative AI social implementation project, led by METI and NEDO, and has advanced to the final screening.

In this project, Ingenta teamed up with Biomimetics Sympathies Inc. to propose "Drug Discovery AI for Assetizing Failure Data: An Autonomous Collaborative Hypothesis Generation System using Domestic LLM x Graph Technology."

This proposal conceptualized and developed an AI system that structures previously underutilized experimental failure data, research records, and literature information, connecting them to hypothesis generation and decision support in R&D. It was selected as a finalist for its evaluation of tacit knowledge inheritance in drug discovery and manufacturing, advancement of R&D processes, and practical implementation potential of generative AI.

Significance of Finalist Selection: Technical Capability and Social Implementability Demonstrated Through Third-Party Review

"GENIAC-PRIZE" is one of Japan's leading projects aimed at accelerating the social implementation of generative AI. "Theme I: Formalization of Tacit Knowledge in Manufacturing," to which Ingenta submitted its proposal, attracted highly advanced proposals from across the country addressing diverse social issues.

Ingenta was selected as one of the 8 finalists out of 58 applications. We interpret this as a result of our technical approach being evaluated not merely as a conceptual proposal, but as one possessing concrete problem-solving potential and social implementability for on-site challenges.

Features of the Proposed Technology: Structured AI that Connects "Failure Data" to Next Outcomes

The core of the solution proposed by Ingenta lies in transforming "failure data" and trial-and-error histories, which have accumulated in R&D sites but have not been fully utilized, into a form that can be reused as knowledge.

・ Assetization of Failure Data

Unstructured data such as experimental failures, review histories, and research notes are structured as knowledge graphs, making them usable as a basis for future hypothesis generation and decision-making. This transforms insights that tend to be buried as individual knowledge into organizational research assets.

・ Integration of Domestic LLM and Graph AI Technology

By combining a domestic LLM that handles specialized Japanese contexts with Graph AI technology capable of representing complex relationships and causal structures, the system can provide structural insights and candidate hypotheses that cannot be obtained through simple document searches.

・ Design Conscious of Implementation in R&D Operations

This proposal is designed with the premise of operational implementation to support researchers' exploration, comparison, and hypothesis generation, not merely information organization. It aims to assist experts' thought processes, reducing research burden and improving decision quality.

Why This Technology is Important: Potential for Industrial Application Beyond Drug Discovery

In drug discovery and regenerative medicine R&D, not only successful cases but also the accumulation of failed trials and condition differences are extremely important. However, this information is often dispersed in documents, tables, and oral knowledge, and is frequently buried without being fully reused.

Ingenta's technology integrates such unorganized knowledge in a reusable form, supporting the improvement of R&D productivity and reproducibility.

This approach is not limited to drug discovery but is also expected to expand into areas where complex knowledge and accumulated trial-and-error determine competitiveness, such as material development, chemistry, food, and manufacturing process improvement.

Participation in "GENIAC-PRIZE Achievement Presentation Caravan"

Following this finalist selection, Ingenta plans to participate in the "GENIAC-PRIZE Achievement Presentation Caravan (Osaka, Nagoya, Fukuoka, Tokyo)" to be held sequentially from March 31, 2026.

On the day, we will introduce our technology concept and usage image through booth exhibits.

We also welcome consultations regarding joint research, proof-of-concept (PoC) experiments, and individual introductions with R&D-intensive companies, including those in drug discovery and manufacturing.

For details on the Achievement Presentation Caravan, please visit the official website.

https://geniac-prize.nedo.go.jp/

Comment from Biomimetics Sympathies Inc.

Keisuke Onishi, President and CEO

"In drug discovery and regenerative medicine R&D, not only successful cases but also the history of failed trials and decisions contain important insights. However, in reality, these are often dispersed in research notes, experimental records, literature, and individual researchers' experiences, and the inability to fully utilize them has been a major challenge.

In this project, which we undertook jointly with Ingenta Inc., we were able to concretely demonstrate the possibility of structuring such dispersed knowledge in a form that is easy for researchers to reuse, and connecting it to hypothesis generation and decision support. In particular, we feel great practical potential in the ability to handle knowledge in line with the on-site thought process, going beyond mere searching or summarization.

We believe that this initiative will not only contribute to the advancement of R&D in the drug discovery and regenerative medicine fields but also represents an approach applicable to a wide range of industrial areas that handle complex technical documents and trial-and-error histories. We are confident that this technology, which will change the way R&D is conducted, will be socially implemented as an effective solution in a wide range of industrial areas in the future."

Comment from Ingenta Inc.

Dennis Hsueh, Representative Director and CEO

"We are deeply honored to have been selected as a finalist for the GENIAC-PRIZE.

Through this proposal, we believe that our technical approach of reusing failure data and tacit knowledge buried in R&D sites as knowledge assets leading to the next outcome has received a certain level of recognition.

This product is being developed with an eye towards applications beyond supporting literature surveys and hypothesis generation, including experimental data analysis. Going forward, we will further deepen its utilization in the drug discovery and regenerative medicine fields, and expand its deployment into related areas such as chemistry, food, and material development, contributing to the advancement of R&D.

Ingenta will continue to steadily implement advanced AI technology in a usable form on-site, contributing to the enhancement of Japanese companies' competitiveness."

Company Overview

Biomimetics Sympathies Inc.

Since 2007, Biomimetics Sympathies Inc. has continuously engaged in cell culture R&D, becoming a leading company in regenerative medicine technology by being the first in the world to realize human and all animal-derived raw material-free culture media optimized for each disease. We collaborate with public research institutions, medical institutions, and pharmaceutical companies to promote the development of new therapies and investigational drugs. We aim to realize a "world without incurable diseases" through regenerative medicine.

https://www.bm-s.biz/

Ingenta Inc.

Ingenta Inc. is an AI company specializing in achieving accuracy for the on-site introduction of advanced AI technology and providing accompanying support for its implementation. In addition to Deep Learning, we have multiple implementation experiences in R&D and business advancement areas through the analysis and utilization of complex knowledge structures using Graph AI.

We are engaged in developing solutions that balance accuracy and implementability in highly specialized fields, including medical/pharmaceutical and manufacturing sectors, and provide flexible AI introduction support tailored to each company's challenges, based on domestic and international knowledge.

https://www.ingenta.ai/ja

Contact for this matter

Ingenta Inc.

Mitsuyoshi Okamoto, Business Development Manager

TEL: 03-5860-6831

Email: info@ingenta.ai

(The content of this press release is as of the announcement date and may be subject to change without notice.)